What is Tesamorelin?
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.
Key Benefits & Mechanisms
FDA-approved for lipodystrophy
Reduces visceral abdominal fat
Physiological GH release pattern
Improved body composition
Cognitive benefits (studied in aging)
Does not suppress natural GH axis
Improved IGF-1 levels
Research Summary
Tesamorelin has robust Phase III clinical evidence. FDA-approved in 2010. Multiple large-scale trials demonstrate significant reduction in trunk fat. Also being studied for cognitive decline in aging populations.